Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
December 03, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
November 12, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
November 04, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare

RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020 HAIFA, Israel, Nov. ...
September 16, 2019 12:20 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantationData from 1st and 2nd...
September 09, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced...
August 21, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
July 31, 2019 08:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome

PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA,...
July 24, 2019 10:45 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics’ CEO Issues Shareholders Update

HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
July 24, 2019 02:45 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces One-for-Ten Reverse Split of its Common Shares

HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...